Synopsis
Use the WHO cancer-pain framework as a flexible guide, combine mechanism-specific medicines with disease treatment, rehabilitation and psychosocial care, and avoid reflex opioid escalation when a different modality offers greater benefit.
- The WHO ladder was developed for cancer pain: non-opioid at step one, opioid for mild-to-moderate pain at step two and strong opioid at step three, with adjuvants throughout.
- Use the ladder flexibly rather than forcing slow progression; severe cancer pain may require a carefully started strong opioid without a prolonged weak-opioid trial.
- Core principles are an appropriate route, regular treatment for continuous pain, rescue for breakthrough pain, individual titration and attention to detail.
- First-line multimodal planning treats the cause and mechanism: radiotherapy, surgery, anti-inflammatory treatment, nerve intervention, rehabilitation and psychological support may reduce drug burden.
- Paracetamol or an NSAID can help selected nociceptive pain, but continue only when repeated review shows benefit greater than hepatic, renal, gastrointestinal or cardiovascular risk.
- Avoid combining two strong opioids routinely or mixing immediate-release products without a single documented total-dose plan.
- Adjuvant analgesics are selected for neuropathic, inflammatory, bone, spasm or pressure mechanisms and need their own titration and adverse-effect monitoring.
- There is no universal gold-standard drug sequence: the benchmark is mechanism-linked analgesia that improves a patient-defined outcome with tolerable harm.
- Chronic primary pain is not managed by importing the cancer ladder; NICE advises against initiating several dependence-forming analgesics for that condition.
Key red flags
New neurological deficit, pathological fracture features or visceral obstruction requires urgent cause-directed treatment rather than analgesic escalation alone.
Respiratory slowing, marked sedation, hallucinations or myoclonus during opioid treatment requires toxicity assessment before the next dose.
NSAID use with acute kidney injury, gastrointestinal bleeding, severe heart failure or anticoagulation may create disproportionate harm.
Combination products can conceal duplicate paracetamol or opioid exposure and cause accidental overdose.
Gabapentinoids, benzodiazepines, alcohol and opioids together increase sedation and respiratory risk, especially with frailty or sleep-disordered breathing.
Persistent severe pain despite rational measures needs specialist review for mechanism, procedure, radiotherapy, opioid rotation or psychological complexity.
Escalating toxicity without functional gain suggests the formulation or target is wrong and warrants specialist reassessment.
Investigation priorities
Identify nociceptive, neuropathic, inflammatory, mechanical and psychosocial contributors and the need for urgent disease treatment.
Management branches
Pain requires a new or revised treatment plan after emergency causes have been addressed.
- Formulate pain mechanisms and severity, define a functional goal and identify disease-directed, physical and psychosocial treatments that can alter the cause.
- Select non-opioid, opioid and adjuvant components with organ function and interactions considered, moving directly to carefully titrated strong opioid when severe cancer pain warrants it.
- Write scheduled and rescue instructions, bowel and nausea support, safety advice and an early review date, then stop components that do not add measurable benefit.